D. E. Shaw & Co., Inc. Astrazeneca PLC Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 14,900 shares of AZN stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,900

Previous 63,800 76.65%

Holding current value

$1.33 Million

Previous $4.46 Million 74.36%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$68.72 - $82.11 $115 Million - $137 Million	-1,673,312 Reduced 87.84%	231,631 $17.8 Million
Q2 2025 Aug 14, 2025	BUY	$64.87 - $75.0 $13.4 Million - $15.5 Million	207,151 Added 12.2%	1,904,943 $133 Million
Q1 2025 May 15, 2025	SELL	$65.37 - $77.96 $205 Million - $244 Million	-3,128,538 Reduced 64.82%	1,697,792 $125 Million
Q4 2024 Feb 14, 2025	BUY	$63.2 - $79.58 $204 Million - $257 Million	3,234,875 Added 203.27%	4,826,330 $316 Million
Q3 2024 Nov 14, 2024	BUY	$76.67 - $87.62 $119 Million - $137 Million	1,558,105 Added 4671.98%	1,591,455 $124 Million

Q2 2024 Aug 14, 2024	BUY	$66.81 - $80.83 $1.11 Million - $1.34 Million	16,631 Added 99.47%	33,350 $2.6 Million
Q1 2024 May 15, 2024	SELL	$61.03 - $69.57 $94.7 Million - $108 Million	-1,551,062 Reduced 98.93%	16,719 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$61.89 - $69.28 $52.5 Million - $58.7 Million	847,501 Added 117.66%	1,567,781 $106 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $43.9 Million - $48.5 Million	676,868 Added 1559.17%	720,280 $48.8 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $2.6 Million - $2.82 Million	37,151 Added 593.37%	43,412 $3.11 Million
Q1 2023 May 15, 2023	SELL	$63.15 - $71.6 $41.7 Million - $47.2 Million	-659,653 Reduced 99.06%	6,261 $434,000
Q4 2022 Feb 14, 2023	BUY	$54.21 - $70.44 $17.1 Million - $22.3 Million	316,045 Added 90.33%	665,914 $45.1 Million
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $18 Million - $46.2 Million	340,026 Added 3454.5%	349,869 $19.2 Million
Q2 2022 Aug 15, 2022	SELL	$59.26 - $71.14 $13.5 Million - $16.2 Million	-227,107 Reduced 95.85%	9,843 $650,000
Q1 2022 May 16, 2022	SELL	$55.72 - $67.12 $32.5 Million - $39.2 Million	-583,993 Reduced 71.14%	236,950 $15.7 Million
Q4 2021 Feb 14, 2022	SELL	$54.02 - $63.83 $19.2 Million - $22.7 Million	-356,161 Reduced 30.26%	820,943 $47.8 Million
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $36.3 Million - $39.7 Million	652,870 Added 124.54%	1,177,104 $70.7 Million
Q2 2021 Aug 16, 2021	BUY	$48.42 - $60.18 $25.4 Million - $31.5 Million	524,234 New	524,234 $31.4 Million
Q1 2021 May 17, 2021	SELL	$47.16 - $54.44 $202 Million - $233 Million	-4,277,572 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$48.52 - $58.02 $205 Million - $246 Million	4,234,797 Added 9900.17%	4,277,572 $214 Million
Q3 2020 Nov 16, 2020	BUY	$53.07 - $61.1 $2.27 Million - $2.61 Million	42,775 New	42,775 $2.34 Million
Q3 2019 Nov 14, 2019	SELL	$40.12 - $45.47 $10.5 Million - $11.9 Million	-262,518 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$37.28 - $41.68 $3.99 Million - $4.46 Million	106,928 Added 68.72%	262,518 $10.8 Million
Q1 2019 May 15, 2019	SELL	$35.49 - $43.02 $4.08 Million - $4.95 Million	-114,964 Reduced 42.49%	155,590 $6.29 Million
Q4 2018 Feb 14, 2019	BUY	$36.86 - $41.49 $9.97 Million - $11.2 Million	270,554 New	270,554 $10.3 Million
Q2 2018 Aug 14, 2018	SELL	$34.55 - $37.05 $373,485 - $400,510	-10,810 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$32.97 - $36.63 $79,391 - $88,205	-2,408 Reduced 18.22%	10,810 $378,000
Q4 2017 Feb 14, 2018	BUY	$32.09 - $34.78 $424,165 - $459,722	13,218	13,218 $459,000

Others Institutions Holding AZN

# of Institutions

1,502

Shares Held

500M

Call Options Held

5.64M

Put Options Held

3.2M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $277B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account